NO970787L - Fremgangsmåte for hemming av primær endometrial hyperplasi - Google Patents

Fremgangsmåte for hemming av primær endometrial hyperplasi

Info

Publication number
NO970787L
NO970787L NO970787A NO970787A NO970787L NO 970787 L NO970787 L NO 970787L NO 970787 A NO970787 A NO 970787A NO 970787 A NO970787 A NO 970787A NO 970787 L NO970787 L NO 970787L
Authority
NO
Norway
Prior art keywords
endometrial hyperplasia
inhibition
procedure
primary endometrial
primary
Prior art date
Application number
NO970787A
Other languages
English (en)
Norwegian (no)
Other versions
NO970787D0 (no
Inventor
Robin Sharon Lee Fuchs-Young
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO970787D0 publication Critical patent/NO970787D0/no
Publication of NO970787L publication Critical patent/NO970787L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO970787A 1994-08-22 1997-02-20 Fremgangsmåte for hemming av primær endometrial hyperplasi NO970787L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29412194A 1994-08-22 1994-08-22
PCT/US1995/010619 WO1996005832A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting primary endometrial hyperplasia

Publications (2)

Publication Number Publication Date
NO970787D0 NO970787D0 (no) 1997-02-20
NO970787L true NO970787L (no) 1997-02-20

Family

ID=23131973

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970787A NO970787L (no) 1994-08-22 1997-02-20 Fremgangsmåte for hemming av primær endometrial hyperplasi

Country Status (20)

Country Link
EP (1) EP0771201B1 (pt)
JP (1) JPH10504579A (pt)
KR (1) KR970705388A (pt)
AT (1) ATE200623T1 (pt)
AU (1) AU706953B2 (pt)
CA (1) CA2198120A1 (pt)
CZ (1) CZ52297A3 (pt)
DE (1) DE69520741T2 (pt)
DK (1) DK0771201T3 (pt)
ES (1) ES2155895T3 (pt)
FI (1) FI970716A (pt)
GR (1) GR3036225T3 (pt)
HU (1) HUT76854A (pt)
IL (1) IL115018A0 (pt)
MX (1) MX9701359A (pt)
MY (1) MY131931A (pt)
NO (1) NO970787L (pt)
PT (1) PT771201E (pt)
WO (1) WO1996005832A1 (pt)
ZA (1) ZA956988B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115022A (en) * 1994-08-22 2000-07-31 Lilly Co Eli Pharmaceutical compositions for inhibiting endometrial cancer
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5461065A (en) * 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
IL111287A0 (en) * 1993-10-15 1994-12-29 Lilly Co Eli Methods for treating resistant neoplasms

Also Published As

Publication number Publication date
FI970716A0 (fi) 1997-02-20
CZ52297A3 (en) 1997-08-13
NO970787D0 (no) 1997-02-20
HUT76854A (en) 1997-12-29
GR3036225T3 (en) 2001-10-31
ZA956988B (en) 1997-02-21
DE69520741D1 (de) 2001-05-23
JPH10504579A (ja) 1998-05-06
CA2198120A1 (en) 1996-02-29
PT771201E (pt) 2001-07-31
FI970716A (fi) 1997-02-20
ATE200623T1 (de) 2001-05-15
MX9701359A (es) 1997-05-31
DE69520741T2 (de) 2001-10-11
DK0771201T3 (da) 2001-05-07
AU706953B2 (en) 1999-07-01
EP0771201A1 (en) 1997-05-07
IL115018A0 (en) 1995-12-08
AU3409895A (en) 1996-03-14
EP0771201A4 (en) 1997-09-10
EP0771201B1 (en) 2001-04-18
ES2155895T3 (es) 2001-06-01
WO1996005832A1 (en) 1996-02-29
KR970705388A (ko) 1997-10-09
MY131931A (en) 2007-09-28

Similar Documents

Publication Publication Date Title
NO943879L (no) Hemming av endometriose
NO943878D0 (no) Hemming av uterinfibrose
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
DK0659416T3 (da) Inhibering af seborE og acne
NO944930D0 (no) Hemming av dysfunksjonell uterin blödning
NO943873D0 (no) Hemming av bruskdegradering
MX9701327A (es) Metodos para inhibir el cancer endometrial.
NO970787D0 (no) Fremgangsmåte for hemming av primær endometrial hyperplasi
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701333A (es) Metodos para inhibir el daño neuronal.
NO944920L (no) Fremgangsmåte for å inhibere hirsutisme og alopecia hos kvinner
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.
MX9706520A (es) Metodos para inhibir el cancer de ovario.